Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-06-2016 | Review Article

Tau imaging in neurodegenerative diseases

Authors: M. Dani, D. J. Brooks, P. Edison

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2016

Abstract

Aggregated tau protein is a major neuropathological substrate central to the pathophysiology of neurodegenerative diseases such as Alzheimer’s disease (AD), frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration and chronic traumatic encephalopathy. In AD, it has been shown that the density of hyperphosphorylated tau tangles correlates closely with neuronal dysfunction and cell death, unlike β-amyloid. Until now, diagnostic and pathologic information about tau deposition has only been available from invasive techniques such as brain biopsy or autopsy. The recent development of selective in-vivo tau PET imaging ligands including [¹⁸F]THK523, [¹⁸F]THK5117, [¹⁸F]THK5105 and [¹⁸F]THK5351, [¹⁸F]AV1451(T807) and [¹¹C]PBB3 has provided information about the role of tau in the early phases of neurodegenerative diseases, and provided support for diagnosis, prognosis, and imaging biomarkers to track disease progression. Moreover, the spatial and longitudinal relationship of tau distribution compared with β - amyloid and other pathologies in these diseases can be mapped. In this review, we discuss the role of aggregated tau in tauopathies, the challenges posed in developing selective tau ligands as biomarkers, the state of development in tau tracers, and the new clinical information that has been uncovered, as well as the opportunities for improving diagnosis and designing clinical trials in the future.

Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–22. doi:10.1016/s1474-4422(13)70090-5.CrossRefPubMed

Gomez-Isla. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41:17–24.CrossRefPubMed

Ingelsson M, Fukumoto H, Newell K, Growdon W, Hedley-White E, Frosch M, et al. Early amyloid accumulation and progressive synaptic loss, gliosis and tangle formation in the Alzheimer’s disease brain. Neurology. 2004;62:925–31.CrossRefPubMed

Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer’s disease: pathogen or protector? Trends Mol Med. 2005;11:164–9. doi:10.1016/j.molmed.2005.02.008.CrossRefPubMed

Giacobini E, Gold G. Alzheimer disease therapy—moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9:677–86. doi:10.1038/nrneurol.2013.223.CrossRefPubMed

Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci. 2007;8:663–72. doi:10.1038/nrn2194.CrossRefPubMed

Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer’s disease. Alzheimer’s Dement: J Alzheimer’s Assoc. 2013;9:452–8. doi:10.1016/j.jalz.2013.01.017. e1.CrossRef

Stoothoff W, Johnson G. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta. 2005;280–97.

Grundke-Iqbal I, Iqbal K, Tung Y-C, Quinlan M, Wisniewski H, Binder L. Abnormal phosporylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913–7.CrossRefPubMedPubMedCentral

10.

Kosik K, Joachim C, Selkoe D. Microtubule-associated protein Tau is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci. 1986;83:4044–8.CrossRefPubMedPubMedCentral

11.

Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067–81. doi:10.1016/j.neuron.2010.11.030.CrossRefPubMedPubMedCentral

12.

Braak H, Braak E. Neuropathological staging of Alzheimer related changes in Alzheimer’s disease. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed

13.

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–7.CrossRefPubMed

14.

Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s Disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712.CrossRefPubMed

15.

Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83. doi:10.1016/j.neurobiolaging.2010.04.007.CrossRefPubMed

16.

Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032–42. doi:10.1002/ana.22333.CrossRefPubMedPubMedCentral

17.

Villemagne V, Pike K, Chetelat G, Ellis K, Mulligan R, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92. doi:10.1002/ana.22248.CrossRefPubMedPubMedCentral

18.

Villemagne V, Burnham S, Bourgeat P, Brown B, Ellis K, Salvado O, et al. Amyloid B deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s Disease: a prospective cohort study. Lancet. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.CrossRefPubMed

19.

Engler H, Forsby A, Almqvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two year follow up of amyloid deposition in patients with Alzheimer’s disease. Brain: J Neurol. 2006;129:2856–66.CrossRef

20.

Ittner LM, Gotz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12:65–72. doi:10.1038/nrn2967.CrossRefPubMed

21.

Price J, Morris J. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45:358–68.CrossRefPubMed

22.

Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science. 2001;293:1491–5. doi:10.1126/science.1062097.CrossRefPubMed

23.

Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487–91. doi:10.1126/science.1058189.CrossRefPubMed

24.

Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, et al. Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol. 2007;171:2012–20. doi:10.2353/ajpath.2007.070403.CrossRefPubMedPubMedCentral

25.

Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845–52. doi:10.1074/jbc.M808759200.CrossRefPubMedPubMedCentral

26.

Novak P, Prcina M, Kontsekova E. Tauons and prions: infamous cousins? J Alzheimer’s Dis: JAD. 2011;26:413–30. doi:10.3233/JAD-2011-110194.CrossRefPubMed

27.

Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord. 2012;18:S192–4. doi:10.1016/s1353-8020(11)70060-8.CrossRefPubMed

28.

Takashima A. Tauopathies and tau oligomers. J Alzheimer’s Dis: JAD. 2013;37:565–8. doi:10.3233/JAD-130653.PubMed

29.

Saito Y, Ruberu N, Sawabe M, Motoji M, Arai T, Tanaka N, et al. Staging of argyrophilic grains — an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63:911–8.CrossRefPubMed

30.

Yamada M, Itoh Y, Sodeyama N, Suematsu N, Otamo E, Matohushita M, et al. Senile dementia of the neurofibrillary tangle type : a comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12:117–26.CrossRefPubMed

31.

Murray M, Kouri N, Lin W, Jack C, Dickson D, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer’s Res Ther. 2014;6(1):1.CrossRef

32.

Gandy S, Ikonomovic M, Mitsis E, Elder G, Ahlers S, Barth J, et al. Chronic traumatic encephalopathy: clinical–biomarker correlations and current concepts in pathogenesis. Mol Degener. 2014;9:37.

33.

McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain: J Neurol. 2013;136:43–64. doi:10.1093/brain/aws307.CrossRef

34.

Liscic RM, Srulijes K, Groger A, Maetzler W, Berg D. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand. 2013;127:362–70. doi:10.1111/ane.12067.CrossRefPubMed

35.

Kovacs G. Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41:3–23.CrossRefPubMed

36.

Rabano A, Rodal I, Cuadros R, Calero M, Hernandez F, Avila J. Argyrophilic grain pathology as a natural model of tau propagation. J Alzheimers Dis. 2014;40:S123–33.PubMed

37.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement: J Alzheimer’s Assoc. 2011;7:280–92. doi:10.1016/j.jalz.2011.03.003.CrossRef

38.

Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W. Mild cognitive impairment. Part 2: biological markers for diagnosis and prediction of dementia in Alzheimer’s disease. Rev Bras Psiquiatr. 2013;35:284–94. doi:10.1590/1516-4446-2012-3505.CrossRefPubMed

39.

Bucchave P, Minthon L, Zetterberg H, Wallin A, Blemar K, Hanson O. Cerebrospinal fluid levels of B-amyloid 1–42 but not of tau are fully changed 5–10 years before the onset of Alzheimer’s disease. Arch Gen Psychiatry. 2012;69:98–106.CrossRef

40.

Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer’s Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord. 2006;21:131–8. doi:10.1159/000090631.CrossRefPubMed

41.

Shah M, Catafau AM. Molecular imaging insights into neurodegeneration: focus on Tau PET radiotracers. J Nucl Med: Off Publi Soc Nucl Med. 2014;55:871–4. doi:10.2967/jnumed.113.136069.CrossRef

42.

Villemagne V, Fodero-Tavoletti M, Masters C, Rowe C. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114–24.CrossRefPubMed

43.

Villemagne V, Furomoto S, Fodero-Tavoletto M, Harada R, Mulligan R, Kudo Y, et al. The challenges of Tau imaging. Future Neurol. 2012;7:409–21.CrossRef

44.

Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep. 2014;14:500. doi:10.1007/s11910-014-0500-6.CrossRefPubMed

45.

Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimer’s Dement: J Alzheimer’s Assoc. 2014;10:S254–64. doi:10.1016/j.jalz.2014.04.013.CrossRef

46.

Barrio J, Kepe V, Satyamurthy N, Huang S, Small G. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J Nutr Health Ageing. 2008;12:61(S)–5(S).CrossRef

47.

Small G, Siddarth P, Kepe V, Ercoli L, Burggren A, Bookheimer S, et al. Prediction of cognitive decline by positron emissions tomography of brain amyloid and Tau. Arch Neurol. 2012;69:215–20.CrossRefPubMedPubMedCentral

48.

Nelson L, Siddarth P, Kepe V, Scheibel K, Huang S, Barrio J, et al. Positron emission tomography of brain B-amyloid and Tau levels in adults with Down Syndrome. Arch Neurol. 2011;68:768–74.CrossRefPubMedPubMedCentral

49.

Smid L, Kepe V, Vinters H, Bresjanac M, Toyokuni T, Satyamurthy N, et al. Postmortem 3-D brain hemisphere cortical tau and amyloid-beta pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimer’s Dis: JAD. 2013;36:261–74. doi:10.3233/JAD-122434.PubMedCentral

50.

Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience. 2003;117:723–30.CrossRefPubMed

51.

Yaqub M, Boellaard R, van Berckel BN, Tolboom N, Luurtsema G, Dijkstra AA, et al. Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. Mol Imaging Biol. 2009;11:322–33. doi:10.1007/s11307-009-0208-1.CrossRefPubMedPubMedCentral

52.

Small G, Kepe V, Ercoli L, Siddarth P, Bookheimer S, Miller K, et al. Positron emission tomography of brain amyloid and Tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63.CrossRefPubMed

53.

Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s Disease. Eur J Nucl Med Mol Imaging. 2014;41:816–26.CrossRefPubMed

54.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain: JNeurol. 2014;137:1762–71. doi:10.1093/brain/awu064.CrossRef

55.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimer’s Dis: JAD. 2013;34:457–68. doi:10.3233/JAD-122059.PubMed

56.

Sperling RMM, Johnson K. The Evolutions of Preclinical Alzheimer’s Disease: Implications for Prevention Trials. Neuron. 2014;84:608–22.CrossRefPubMedPubMedCentral

57.

Mintun M, Devous M, Pontecorvo M, Joshi A, Siderowf A, Johnson K, et al. Potential for PET Imaging Tau Tracer 18F-AV-1451 (also known as 18F-T807) to Detect Neurodegenerative Progression in Alzheimer’s Disease. Human Amyloid Imaging Conference Book of Abstracts 2015 Submission ID 95. 2015:87.

58.

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108. doi:10.1016/j.neuron.2013.07.037.CrossRefPubMed

59.

Okamura NST, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, et al. Quinoline and benzimidazole derivatives: candiate probes for in vivo imaging of tau pathology in Alzheimer’s Disease. J Neurosci. 2005;25:10857–62.CrossRefPubMed

60.

Villemagne V, Furumoto S, Fodero-Tavoletti M, Mulligan R, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2014;41:816–26. doi:10.1007/s00259-013-2681-7.CrossRefPubMed

61.

Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [18F]THK523 and other amyloid imaging tracers to Alzheimer’s Disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125–32.CrossRefPubMed

62.

Fodero-Tavoletti M, Okamura N, Furumoto S, Mulligan R, Connor A, McLean C, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain: J Neurol. 2011;134:1089–100. doi:10.1093/brain/awr038.CrossRef

63.

Fodero-Tavoletti M, Furomoto S, Taylor L, McLean C, Mulligan R, Buchal I, et al. Assessing THK523 selectivity for Tau deposits in Alzheimer’s disease and non-Alzheimer’s disease tauopathies. Alzheimer’s Res Ther. 2014;6.

64.

Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med: Off Publ Soc Nucl Med. 2013;54:1420–7. doi:10.2967/jnumed.112.117341.CrossRef

65.

Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40. doi:10.1186/s40478-015-0220-4.CrossRefPubMedPubMedCentral

66.

Nordberg A, Chiotis K, Aubert L, Wall A, Jonasson M, Lubberink M, et al. Tau Imaging with [18F]-(S)-THK5117 in MCI and AD Patients Using a PET Multii-Tracer Concept. Human Amyloid Imaging Conference Book of Abstracts 2015 ID submission 106. 2015:124.

67.

Saint-Aubert L, Lemoine L, Marutle A, Antoni G, Eriksson J, Okamura N, et al. Relationship between Post-Mortem THK5117 Binding and In-Vivo PET Biomarkers Uptake in Alzheimer’s Disease. Human Amyloid Imaging Conference Book of Abstracts 2015 ID submission 94. 2015:94.

68.

Harada R, Okamura N, Furumoto S, Tago T, Furukawa K, Ishiki A, et al. First-in-human PET Study of a Novel Tau Tracer [18F]THK5351. Human Amyloid Imaging Conference Book of Abstracts 2015 Submission ID 24. 2015.

69.

Tago TFS, Okamura N, Harada R, Ishikawa Y, Arai H, Yanai K, et al. Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Labelled Comp Radiopharm. 2014;57:18–24.CrossRefPubMed

70.

Gao M, Wang M, Zheng QH. Concise and high-yield synthesis of T808 and T808P for radiosynthesis of [(18)F]-T808, a PET tau tracer for Alzheimer’s disease. Bioorg Med Chem Lett. 2014;24:254–7. doi:10.1016/j.bmcl.2013.11.025.CrossRefPubMed

71.

Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimer’s Dis: JAD. 2012;31:601–12. doi:10.3233/JAD-2012-120712.PubMed

72.

Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimer’s Dis: JAD. 2014;38:171–84. doi:10.3233/JAD-130098.PubMed

73.

Kolb H, Attardo G, Mintun M, Chien D, Elizarov A, Conti P, et al. First case report: image to autopsy correlation for tau imaging with [18F]-T808 (AV-680). Alzheimers Dement. 2013;9:P844–5. doi:10.1016/j.jalz.2013.08.008.CrossRef

74.

Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimer’s Dement: J Alzheimer’s Assoc. 2013;9:666–76. doi:10.1016/j.jalz.2012.11.008.CrossRef

75.

Marquie M, Normandin M, Vanderburg C, Costantino I, Dickerson B, Frosch M, et al. Towards the Validation of Novel PET tracer T807 on Postmortem Human Brain Tissue Samples. Abstract Online: Human Amyloid Imaging Book of Abstracts 2015 Submission ID 89. 2015:28.

76.

Pontecorvo M, Devous M, Joshi A, Lu M, Siderowf A, Arora A, et al. Relationships between Florbetapir PET Amyloid and 18F AV-1451 (aka 18F-T807) PET Tau Binding in Cognitively Normal Subjects and Patients with Cognitive Impairment Suspected of Alzheimer’s Disease. Human Amyloid Imaging Conference Book of Abstracts 2015 ID submission 98. 2015:131.

77.

Johnson K, Becker J, Sepulcre J, Rentz D, Schultz A, Pepin L, et al. Tau PET: Initial Experience with F18 T807. Human Amyloid Imaging Conference Book of Abstracts 2014 ID submission 103. 2014:22.

78.

Ossenkoppele R, Schonhaut D, Baker S, O’Neil J, Janabi M, Ghosh P, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2014. doi:10.1002/ana.PubMedPubMedCentral

79.

Ossenkoppele R, Schonhaut D, Baker S, Lazaris A, Ayakte N, Cantwell A, et al. Distinct [18F]AV1451 Retention Patterns in Clinical Variants of Alzheimer’s Disease. Human Amyloid Imaging Conference Book of Abstracts 2015 P55 Submission 113 2015:62.

80.

Dickerson B, McGinnis S, Gomperts S, Caso C, Makaretz S, Kelly K, et al. [18F]T807 of Frontotemporal Lobar Degeneration. Human Amyloid Imaging Conference Book of Abstracts 2015 P15 Submission ID 61. 2015:37.

81.

Gomperts S, Makaretz S, Schultz A, Caso C, McGinnis S, Growdon J, et al. [18F] T807 PET Imaging of Hyperphosphorylated Tau to Differentiate PSP from PD. Human Amyloid Imaging Conference Book of Abstracts 2015 ID submission118. 2015:111.

82.

Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry. 2014;4, e441. doi:10.1038/tp.2014.91.CrossRefPubMedPubMedCentral

83.

Schultz A, Chhatwal J, Mormino E, LaPoint M, Dagley A, Sperling R, et al. Relationship between longitudinal amyloid accumulation and T807-Tau. Human Amyloid Imaging Conference Book of Abstracts 2015 P65 Submission ID 101. 2015:68.

84.

Sperling R, Mormino E, Rentz D, Schultz A, Becker A, Hedden J, et al. T807 PET Measures of Tau Pathology Associated with Episodic Memory Performance among Clinically Normal Older Individuals. Human Amyloid Imaging Conference Book of Abstracts 2015 ID submission 123. 2015:93.

85.

Chhatwal J, Schultz A, Marshall G, Boot B, Gomez-Isla T, Dumurgier J, et al. Entorhinal, Parahippocampal, and Inferior Temporal F18-T807 SUVR Correlates with CSF Total Tau and Tau T181P in Cognitively Normal Elderly. Human Amyloid Imaging Conference Book of Abstracts 2015 Submission ID 115. 2015:88.

86.

Lockhart S, Vogel J, Schonhaut D, Baker S, Schwimmer H, Scholl M, et al. Effects of Age and B-Amyloid on Tau Deposition Measured Using [18F]AV-1451 in Normal Older People. Human Amyloid Imaging Conference Book of Abstracts 2015 P41 Submission ID 55. 2015:54.

87.

Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med: Off Publ Soc Nucl Med. 2014;55:1532–8. doi:10.2967/jnumed.114.139550.CrossRef

88.

Kimura Y, Ichise M, Ito H, Shimada H, Ikoma Y, Seki C, et al. PET quantification of Tau pathology in human brain with 11C-PBB3. J Nucl Med: Off Publ Soc Nucl Med. 2015. doi:10.2967/jnumed.115.160127.

89.

Shimada H, Higuchi M, Ikoma Y, Shinotoh H, Furukawa S, Moriguchi S, et al. In vivo visualization of tau pathology. Alzheimers Dement. 2013;9:P101–2. doi:10.1016/j.jalz.2013.05.172.CrossRef

90.

Honer M, Knust H, Gobbi L, Kuwubara H, Muri D, Valentine H, et al. In Vitro and In vivo Evaluation of RO6931643, RO6924963 and RO6958948 Candidate PET Tracers for Aggregated Tau. Human Amyloid Imaging Conference Book of Abstracts 2015 ID submission 34. 2015:114.

Title: Tau imaging in neurodegenerative diseases
Authors: M. Dani
D. J. Brooks
P. Edison
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3231-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tau imaging in neurodegenerative diseases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans

Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging

Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer

Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy

18F-DOPA: the versatile radiopharmaceutical

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer